Profund Advisors LLC Acquires 5,358 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Profund Advisors LLC boosted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 13.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 45,432 shares of the biopharmaceutical company’s stock after buying an additional 5,358 shares during the period. Profund Advisors LLC’s holdings in Cytokinetics were worth $1,482,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Belpointe Asset Management LLC lifted its stake in Cytokinetics by 76.2% during the first quarter. Belpointe Asset Management LLC now owns 786 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 340 shares during the last quarter. Archer Investment Corp bought a new stake in Cytokinetics during the first quarter worth about $51,000. Natixis bought a new stake in Cytokinetics during the fourth quarter worth about $73,000. Chilton Capital Management LLC bought a new stake in Cytokinetics during the first quarter worth about $80,000. Finally, Captrust Financial Advisors lifted its stake in Cytokinetics by 79.8% during the first quarter. Captrust Financial Advisors now owns 3,910 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 1,735 shares during the last quarter.

Cytokinetics Stock Performance

CYTK stock opened at $32.31 on Tuesday. Cytokinetics, Incorporated has a fifty-two week low of $25.98 and a fifty-two week high of $47.49. The business’s 50 day moving average price is $32.59 and its two-hundred day moving average price is $34.25. The company has a market capitalization of $3.17 billion, a price-to-earnings ratio of -5.85 and a beta of 0.63.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $58.00 price objective on shares of Cytokinetics in a report on Wednesday, November 1st. Cantor Fitzgerald lifted their price objective on Cytokinetics from $59.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, October 9th. The Goldman Sachs Group assumed coverage on Cytokinetics in a report on Thursday, November 9th. They issued a “buy” rating and a $50.00 price objective on the stock. B. Riley started coverage on Cytokinetics in a report on Tuesday, November 7th. They issued a “buy” rating and a $66.00 price objective on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $60.00 price target on shares of Cytokinetics in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $59.87.

Insider Transactions at Cytokinetics

In related news, EVP Fady Ibraham Malik sold 2,500 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $34.86, for a total value of $87,150.00. Following the transaction, the executive vice president now directly owns 155,664 shares of the company’s stock, valued at approximately $5,426,447.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Cytokinetics news, EVP Fady Ibraham Malik sold 2,500 shares of the business’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $34.86, for a total transaction of $87,150.00. Following the completion of the sale, the executive vice president now directly owns 155,664 shares in the company, valued at approximately $5,426,447.04. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Robert I. Blum sold 12,500 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $34.57, for a total transaction of $432,125.00. Following the sale, the chief executive officer now owns 441,417 shares of the company’s stock, valued at $15,259,785.69. The disclosure for this sale can be found here. Insiders have sold a total of 82,500 shares of company stock valued at $2,757,000 in the last ninety days. 3.80% of the stock is currently owned by corporate insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.